Recovery & Longevity · BRIEFING
Longevity Goes Investable: €95M War Chests, Sleep Capital and the First Payers
Lanserhof's €95 million capital injection funds a global clinic rollout while sleep tech draws Series B money and health systems in three countries begin paying for structured exercise — recovery is becoming a reimbursement-grade service line.
Longevity medicine has spent years functioning as a billionaire amenity — clinics that existed where the clients already were, priced for a client list, not a market. The current data says that phase is ending on two fronts at once. Institutional capital is now funding clinic groups to scale across borders, and public health systems have started paying for structured exercise as though it were medicine. For the recovery economy, the direction of travel is the same from both ends: from spa menu to service line.
Lanserhof’s €95M rollout
Lanserhof, the luxury longevity clinic group, has secured a €95 million capital injection to open several new locations by 2030 and to launch premium nutrition supplements and cosmetics, citing accelerating global demand for preventive health and longevity medicine. The funding came through an AltamarCAM Partners vehicle anchored by King Street Capital Management. The build-out includes three flagship resorts in Germany and Austria plus a Marbella site opening in 2027.
“…provide resources and expertise to strengthen our presence in Europe while expanding our footprint into new regions globally where demand for high-quality preventive health and longevity solutions is accelerating.”
— Dr Christian Harisch, CEO, Lanserhof
The structure of the deal matters as much as its size. An institutional vehicle anchored by a credit manager, deployed against a dated pipeline of new sites and product lines, treats a longevity clinic group as an investable, replicable format — resorts first, then branded retail supplements and cosmetics — rather than a one-off destination for the wealthy. That is how a category stops being a curiosity for allocators and starts being a chain business.
Sleep tech draws its own capital
The recovery economy’s capital story does not stop at clinics. Ozlo, the sleep-technology company, raised $22 million in Series B funding to expand its Sleepbuds and sleep-condition ecosystem, having passed 200,000 customers. The company builds on acquired Bose audio IP and holds partnerships with Calm and Dreem Health — a distribution stack that runs from consumer audio into clinical sleep care.
The shape of the round is the signal. Series B capital arrived on the strength of a hardware-plus-services ecosystem with a six-figure customer base, not a gadget launch. Sleep is the largest single surface in recovery, and investors are now pricing it as a platform category: audio hardware at one end, clinical partnerships at the other, subscription behaviour in between.
The payers arrive
The structural shift sits with the payers, and it is already written into three national systems. Medicare now reimburses standardized physical activity assessments inside the US Annual Wellness Visit. Australia has reintroduced private-insurance rebates for selected therapies such as Pilates. Japan allows selected expenses at government-certified exercise therapy facilities to count as tax-deductible medical expenses.
Three countries, three mechanisms — direct reimbursement, insurance rebate, tax deduction — and one direction of travel: structured exercise is entering the paid-for layer of the health system. The HFA’s 2026 Global Report, which documents all three, frames this as part of the wider recognition of physical activity as essential to long-term health — and the mechanics matter more than the framing. Amenity revenue is discretionary and cyclical; a member cancels the recovery add-on before they cancel the gym. Reimbursed or tax-preferred revenue is contracted, and it arrives with clinical standards attached.
What to watch
Whether Lanserhof’s cross-border rollout — Marbella in 2027, new locations through 2030 — pulls competing clinic groups into comparable institutional raises and turns longevity medicine into a genuinely chain-operated category. Whether sleep tech consolidates around ecosystem players with clinical distribution, following the Ozlo pattern of hardware, app and health-system partnerships. And whether more health systems follow Medicare, the Australian insurers and Japan’s tax code in paying for structured exercise — because the moment exercise is reimbursed at scale, every operator with a credentialed, structured program becomes part of the health economy’s supply chain rather than its discretionary spend.